<DOC>
	<DOCNO>NCT00083785</DOCNO>
	<brief_summary>The purpose study determine whether Litx™ system safe effective combination chemotherapy treatment liver metastasis arise colorectal cancer . Litx™ next-generation photodynamic therapy platform drug , talaporfin sodium ( LS11 ) , activate light light-emitting diode ( LED ) -based light infusion device , insert directly tumor skin prior treatment .</brief_summary>
	<brief_title>Study Litx™ System Combined With Chemotherapy Patients With Colorectal Liver Metastases</brief_title>
	<detailed_description>Patients provide Informed Consent satisfy Eligibility Criteria undergo CT Ultrasound guide percutaneous placement single , two , three , four Light Sources depend tumor characteristic . No 4 Light Sources use single treatment . The Light Sources may use single lesion multiple lesion . Following radiographic confirmation Light Source placement , patient receive intravenous dose LS11 40 mg/m² . Fifteen minute 1 hour follow completion LS11 administration , delivery 200 J/cm 20 mW/cm light energy begin . The Light Source manually remove patient observe acute complication Light Source removal . Precautions protection external light exposure institute begin LS11 administration maintain define throughout study period . On day 3 follow Litx™ treatment patient receive standard chemotherapy Irinotecan Oxaliplatin without 5FU /or leucovorin metastatic colorectal cancer . On day 30+5 day 60+5 patient undergo clinical assessment tumor mass image use contrast enhance spiral CT determination volume radius PDT necrosis .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Talaporfin</mesh_term>
	<criteria>Patients metastatic liver lesion colorectal disease Biopsy prove evidence colorectal cancer Patients 4 few lesion great 1 cm single lesion great 7 cm maximum diameter Age great equal 18 year Patients must able sign inform consent Life expectancy great equal 3 month ECOG performance status 02 Patients extrahepatic disease addition hepatic metastasis may eligible Must recover toxicity prior antineoplastic therapy Patients candidate complete surgical resection Pregnancy breastfeeding . A negative pregnancy test ( urine serum ) require prior enrollment Known uncontrollable serious reaction anaphylaxis , contrast agent use study PT PTT great 1.5X control Platelet count le 100,000 WBC less 2500/mm Neutrophils less 2000/mm Hemoglobin less 9 g/dL Liver enzymes ( AST , ALT , GGT , alkaline phosphatase ) great 3 X ULN Total bilirubin great 1.5 X ULN Serum creatinine great 2.5 X ULN Patients treat either AVASTIN™ ( Bevacizumab ) ERBITUX™ ( Cetuximab ) within previous 4 week ( 28 day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>